Estimates are derived using Cox proportional-hazards models (Cox, 1972), a regression model commonly used in medical research for investigating the association between the survival time of patients and one or more predictor variables. Survival models relate the time that passes, before some event occurs, to one or more covariates that may be associated with that quantity of time. In a proportional hazards model, the unique effect of a unit increase in a covariate is multiplicative with respect to the hazard rate.
Frequently Asked Questions
If you don't find the answer you're looking for, submit a question below.
About the service
What is MyCancerJourney?
MyCancerJourney is a private patient advocacy service supporting you and your loved ones through every stage of cancer, from diagnosis to treatment and beyond.
How does MyCancerJourney work?
You’ll be connected with a cancer-specialized patient advocate — someone who’s not only skilled in the medical world but deeply understands what you’re going through. They’ll cut through the medical jargon, helping you understand your diagnosis and the options before you and connect you with the education, medical, emotional, social, financial, and practical resources you need.
Who is eligible for MyCancerJourney?
MyCancerJourney advocacy service is available to any adult (18 years or older) diagnosed with cancer.
How often do I have to talk to this advocate?
Your MyCancerJourney advocate will be as involved as you want them to be. Some members may have needs and questions that only require a few conversations, while others need long term support. Your advocate is available to you for as long as you need them.
What can MCJ do for me that I can not research and do for myself?
MyCancerJourney (MCJ) provides expert advocacy that goes beyond what most individuals can easily find on their own. Our advocates, with years of experience, streamline the process of researching cancer treatments, side effects, clinical trials, and second opinions, saving you time and ensuring no critical information is missed.
Additionally, our advocates have access to Capire360, a real-world data tool, they deliver personalized insights based on outcomes from people with similar characteristics, offering tailored, nuanced information not easily accessible through online searches. MCJ allows you to focus on your well-being while we handle the complexities.
Doesn’t my oncologist’s office already provide something like this?
We are private advocates. While most healthcare systems, insurance companies, and nonprofits offer nurse navigators, care coordinators and advocates, our private advocates are different in that their responsibility is solely to you, rather than an institution. This means our advocates provide whole person support to meet your personalized needs. They are not time constrained. They work alongside your care team. They can truly focus on you and dedicate the time needed to support your medical, emotional, financial, social and caregiver needs.
How do I get access to MyCancerJourney?
MyCancerJourney is free to members whose health plan, provider, or employer has an existing partnership with MyCancerJourney.
For those without coverage, a self-pay option is available. Complete the enrollment form and a representative will reach out to you within one business day.
How much does MyCancerJourney cost?
MyCancerJourney is free to members whose health plan or provider has an existing partnership with MyCancerJourney.
For those without coverage, a self-pay option is available.
To determine eligibility, complete the enrollment form and a representative will reach out to you within one business day.
How do I know I can trust the information MyCancerJourney provides?
All of our advocates are PACB-certified with specialties in cancer. Beyond this, each of our advocates is internally screened for expertise and clinical literacy, has extensive personal and professional experience with the oncology system, and is trained on Capire360. They are overseen by our Chief Medical Officer, who specializes in oncological emergency medicine and supported by our clinical advisory board. All resources and information provided has been vetted for medical accuracy and reliability.
Technical Questions about Capire360
Where does the data come from?
Estimates are derived from over 2-million cases from 500 hospitals and cancer treatment centers, ambulatory surgery centers, clinical laboratories, as well as physician and other outpatient offices. Collection and reporting standards are in accordance with the National Program of Cancer Registries (NPCR); Centers for Disease Control and Prevention (CDC); North American Association of Central Cancer Registries (NAACCR); Surveillance, Epidemiology, and End Results Program (SEER) of the National Cancer Institute (NCI); and the American College of Surgeons (ACoS).
How are survival estimates calculated?
Do the estimates pull from clinical trial information?
No. Because treatment trials limited by recruitment, typically exclude patients with comorbidity and fail to differentiate populations based on sex, age and race.
Has the program been validated by a third-party institution or similar?
The data used for Capire360 models have been both internally and externally validated.
Internal validation involves splitting the data up into a training set and a separate test set. Once the model has been trained, it is validated against the test set.
Statistical accuracy has been estimated using the model’s concordance and external validation of the methods used.
The MyCancerJourney analytic platform was developed and back-tested over the past decade. Experts have validated the models in healthcare analytics at the University of Rotterdam, Erasmus. Ewout Steyerberg is a Professor of Medical Decision Making, particularly prognostic modeling, at Erasmus MC–University Medical Center Rotterdam, the Netherlands. Professor Steyerberg is one of the world’s leading experts on validating prognostic modes in medicine. Various research grants stimulated his work on prediction models, including a fellowship from the Royal Netherlands Academy of Arts and Sciences. He has published over 500 peer-reviewed articles collaborating with many clinical researchers in methodological and medical journals.
The Erasmus team performed internal and external validation of the models for the four most prevalent cancer sites (breast, prostate, colorectal, and lung). Internal validation, based on 100 bootstrap samples, demonstrated that the models provided an accurate survival prediction with an average optimism of 0.01 around the c-indices with values ranging from 0.005 to 0.01.
The model’s clinical significance was validated through reviews by oncologists, and it has been compared to the NCI SEER and American Cancer Society outcomes data.
Statistical accuracy has been estimated using the model’s concordance. These models have been validated by experts at Erasmus Medical Center, Rotterdam, Netherlands. The model’s clinical significance was validated through reviews by oncologists.
What cancer sites are included in your model?
Capire360 has models to support the following solid tumor cancer sites.
- Breast
- Prostate
- Colon
- Lung
- Rectum
- Cervix
- Ovary
- Uterus
- Stomach
- Liver
- Bladder
- Kidney
- Head and Neck
- Thyroid
- Pancreas
These are the most common solid tumor cancer sites and represent about 80% of all adult patients with cancer.
Still Have Questions?
Click below to submit a question and a representative will be in touch within one business day.
Get in Touch
We're here to help. Reach out and a MyCancerJourney team member will be in touch within one business day.
Our business hours are Monday-Friday 8:00 AM - 5:00 PM CT.
Our business hours are Monday-Friday 8:00 AM - 5:00 PM CT.
Office
901 S. Mopac Expy.
Bldg. 1, Ste. 300
Austin, TX 78746
Bldg. 1, Ste. 300
Austin, TX 78746
Email us
info@mycancerjourney.com
Call us
737 307 0077